Answers are grounded in this paper and cite their sources.
Prostate cancer is the most common malignancy among men in the United States. With rising survivorship, there is a growing need to identify prognostic factors beyond tumor characteristics. Frailty, a multidimensional syndrome of reduced physiological reserve, is a strong predictor of adverse outcomes, but its role in prostate cancer survivorship is not well established. We analyzed data from the National Health Interview Survey (NHIS) (1997–2018), linked to mortality follow-up through December 31, 2019. Frailty was assessed using the FRAIL scale (fatigue, resistance, ambulation, illness burden, and low body mass index), classifying survivors as robust (score 0), pre-frail (1–2), or frail (3–5). Survey-weighted Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality, adjusting for sociodemographic factors, health insurance, marital status, geographic region, depression, time since diagnosis, and number of cancer diagnoses. Kaplan–Meier methods were used to evaluate survival probabilities across frailty categories. Among 5994 prostate cancer survivors, 74.3% were robust, 14.8% pre-frail, and 10.9% frail. Compared with cancer-free men (n = 269,236), prostate cancer survivors had a significantly higher prevalence of frailty (25.7 vs 9.7%, P < .001). Kaplan–Meier analyses demonstrated clear separation of survival curves by frailty category, with robust individuals consistently showing the most favorable outcomes (log-rank P < .001). In multivariable-adjusted Cox models, pre-frailty was associated with a 40% increased mortality risk (HR, 1.40; 95% CI, 1.34–1.47), and frailty with a 75% increase (HR, 1.75; 95% CI, 1.54–1.99), compared with robust survivors. Age-stratified analyses revealed that both pre-frailty (HR, 1.42; 95% CI, 1.36–1.50) and frailty (HR, 1.68; 95% CI, 1.46–1.93) predicted mortality in men aged ≥ 60 years. In men younger than 60 years, pre-frailty was not significant (HR, 1.10; 95% CI, 0.89–1.36), whereas frailty was strongly associated with risk, more than doubling mortality (HR, 2.35; 95% CI, 1.46–3.79). Frailty was independently associated with a higher risk of all-cause mortality among prostate cancer survivors, with a particularly strong association observed among younger men. These findings support the potential value of frailty assessment for risk stratification in survivorship care, although residual confounding by unavailable cancer-specific clinical characteristics cannot be excluded.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: